Cargando…
High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451950/ https://www.ncbi.nlm.nih.gov/pubmed/34552949 http://dx.doi.org/10.3389/fmed.2021.735853 |
| _version_ | 1784569962376986624 |
|---|---|
| author | Moreira-Soto, Andres Arguedas, Mauricio Brenes, Hebleen Buján, Willem Corrales-Aguilar, Eugenia Díaz, Cecilia Echeverri, Ann Flores-Díaz, Marietta Gómez, Aarón Hernández, Andrés Herrera, María León, Guillermo Macaya, Román Kühne, Arne Molina-Mora, José Arturo Mora, Javier Sanabria, Alfredo Sánchez, Andrés Sánchez, Laura Segura, Álvaro Segura, Eduardo Solano, Daniela Soto, Claudio Stynoski, Jennifer L. Vargas, Mariángela Villalta, Mauren Reusken, Chantal B. E. M. Drosten, Christian Gutiérrez, José María Alape-Girón, Alberto Drexler, Jan Felix |
| author_facet | Moreira-Soto, Andres Arguedas, Mauricio Brenes, Hebleen Buján, Willem Corrales-Aguilar, Eugenia Díaz, Cecilia Echeverri, Ann Flores-Díaz, Marietta Gómez, Aarón Hernández, Andrés Herrera, María León, Guillermo Macaya, Román Kühne, Arne Molina-Mora, José Arturo Mora, Javier Sanabria, Alfredo Sánchez, Andrés Sánchez, Laura Segura, Álvaro Segura, Eduardo Solano, Daniela Soto, Claudio Stynoski, Jennifer L. Vargas, Mariángela Villalta, Mauren Reusken, Chantal B. E. M. Drosten, Christian Gutiérrez, José María Alape-Girón, Alberto Drexler, Jan Felix |
| author_sort | Moreira-Soto, Andres |
| collection | PubMed |
| description | SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment. |
| format | Online Article Text |
| id | pubmed-8451950 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84519502021-09-21 High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern Moreira-Soto, Andres Arguedas, Mauricio Brenes, Hebleen Buján, Willem Corrales-Aguilar, Eugenia Díaz, Cecilia Echeverri, Ann Flores-Díaz, Marietta Gómez, Aarón Hernández, Andrés Herrera, María León, Guillermo Macaya, Román Kühne, Arne Molina-Mora, José Arturo Mora, Javier Sanabria, Alfredo Sánchez, Andrés Sánchez, Laura Segura, Álvaro Segura, Eduardo Solano, Daniela Soto, Claudio Stynoski, Jennifer L. Vargas, Mariángela Villalta, Mauren Reusken, Chantal B. E. M. Drosten, Christian Gutiérrez, José María Alape-Girón, Alberto Drexler, Jan Felix Front Med (Lausanne) Medicine SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment. Frontiers Media S.A. 2021-09-06 /pmc/articles/PMC8451950/ /pubmed/34552949 http://dx.doi.org/10.3389/fmed.2021.735853 Text en Copyright © 2021 Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Kühne, Molina-Mora, Mora, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Reusken, Drosten, Gutiérrez, Alape-Girón and Drexler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Medicine Moreira-Soto, Andres Arguedas, Mauricio Brenes, Hebleen Buján, Willem Corrales-Aguilar, Eugenia Díaz, Cecilia Echeverri, Ann Flores-Díaz, Marietta Gómez, Aarón Hernández, Andrés Herrera, María León, Guillermo Macaya, Román Kühne, Arne Molina-Mora, José Arturo Mora, Javier Sanabria, Alfredo Sánchez, Andrés Sánchez, Laura Segura, Álvaro Segura, Eduardo Solano, Daniela Soto, Claudio Stynoski, Jennifer L. Vargas, Mariángela Villalta, Mauren Reusken, Chantal B. E. M. Drosten, Christian Gutiérrez, José María Alape-Girón, Alberto Drexler, Jan Felix High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title_full | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title_fullStr | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title_full_unstemmed | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title_short | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern |
| title_sort | high efficacy of therapeutic equine hyperimmune antibodies against sars-cov-2 variants of concern |
| topic | Medicine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451950/ https://www.ncbi.nlm.nih.gov/pubmed/34552949 http://dx.doi.org/10.3389/fmed.2021.735853 |
| work_keys_str_mv | AT moreirasotoandres highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT arguedasmauricio highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT breneshebleen highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT bujanwillem highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT corralesaguilareugenia highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT diazcecilia highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT echeverriann highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT floresdiazmarietta highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT gomezaaron highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT hernandezandres highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT herreramaria highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT leonguillermo highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT macayaroman highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT kuhnearne highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT molinamorajosearturo highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT morajavier highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT sanabriaalfredo highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT sanchezandres highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT sanchezlaura highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT seguraalvaro highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT seguraeduardo highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT solanodaniela highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT sotoclaudio highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT stynoskijenniferl highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT vargasmariangela highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT villaltamauren highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT reuskenchantalbem highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT drostenchristian highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT gutierrezjosemaria highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT alapegironalberto highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern AT drexlerjanfelix highefficacyoftherapeuticequinehyperimmuneantibodiesagainstsarscov2variantsofconcern |